Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2004 / Article

Special Article | Open Access

Volume 18 |Article ID 326767 | https://doi.org/10.1155/2004/326767

Richard Hunt, Carlo Fallone, Sander Veldhuyzan van Zanten, Phil Sherman, Fiona Smaill, Nigel Flook, Alan Thomson, all participants of CHSG 2004, "Canadian Helicobacter Study Group Consensus Conference: Update on the Management of Helicobacter pylori - An Evidence-Based Evaluation of Six Topics Relevant to Clinical Outcomes in Patients Evaluated for H pylori Infection", Canadian Journal of Gastroenterology and Hepatology, vol. 18, Article ID 326767, 8 pages, 2004. https://doi.org/10.1155/2004/326767

Canadian Helicobacter Study Group Consensus Conference: Update on the Management of Helicobacter pylori - An Evidence-Based Evaluation of Six Topics Relevant to Clinical Outcomes in Patients Evaluated for H pylori Infection

Received05 Feb 2004
Accepted08 Jul 2004

Abstract

As an update to previously published recommendations for the management of Helicobacter pylori infection, an evidence-based appraisal of six topics was undertaken in a consensus conference sponsored by the Canadian Helicobacter Study Group. The issues addressed and recommendations made were: bismuth-containing quadruple therapy is appropriate as an alternative first-line eradication strategy for H pylori infection; searching for and treating H pylori infection is warranted in patients considered to be at high risk for gastric cancer; H pylori infection should be eradicated before initiating long-term treatment with nonsteroidal anti-inflammatory drugs or acetylsalicylic acid; the stool antigen test has a limited role in the diagnosis of H pylori infection; the benefits of H pylori eradication in patients on long-term proton pump inhibitor therapy are not sufficient to warrant recommending a strategy of searching for and eradicating the infection among these patients; and a strategy of 'test and eradicate' for H pylori infection in patients with uninvestigated dyspepsia is cost-effective in Canada relative to a trial of proton pump inhibitor therapy. The goal was to establish guidelines on the best evidence using the same structure to address and formulate recommendations for each issue. The degree of consensus for each issue is presented.

Copyright © 2004 Canadian Association of Gastroenterology. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution, and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views77
Downloads564
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.